GlycoMimetics, Inc. (GLYC): Price and Financial Metrics
GLYC Price/Volume Stats
| Current price | $0.23 | 52-week high | $3.53 |
| Prev. close | $0.21 | 52-week low | $0.14 |
| Day low | $0.20 | Volume | 1,034,800 |
| Day high | $0.25 | Avg. volume | 6,609,522 |
| 50-day MA | $0.30 | Dividend yield | N/A |
| 200-day MA | $0.68 | Market Cap | 15.08M |
GLYC Stock Price Chart Interactive Chart >
GlycoMimetics, Inc. (GLYC) Company Bio
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. The company was founded in 2003 and is based in Rockville, Maryland.
GLYC Price Returns
| 1-mo | -28.13% |
| 3-mo | 39.56% |
| 6-mo | -13.73% |
| 1-year | -90.94% |
| 3-year | -85.16% |
| 5-year | -95.83% |
| YTD | -90.25% |
| 2023 | -22.11% |
| 2022 | 110.42% |
| 2021 | -61.70% |
| 2020 | -28.92% |
| 2019 | -44.14% |
Loading social stream, please wait...